lindberg
excel
review
histori
live
bacteri
vaccin
first
use
live
bacteri
vaccin
spain
consist
subcutan
inject
weaken
vibrio
cholera
studi
follow
year
later
field
trial
india
efficaci
v
cholera
vaccin
howev
still
parenter
first
live
oral
v
cholera
vaccin
candid
appear
later
v
cholera
strain
cvd
hgr
found
safe
immunogen
singl
oral
dose
bival
vaccin
waspres
includ
two
strain
v
cholera
call
cvd
hgr
cvd
howev
later
problem
attenu
strain
cvd
appear
develop
regist
live
bacteri
vaccin
began
hgin
earli
use
variou
live
attenu
typhi
vaccin
typhoid
fever
one
propos
strain
made
streptomycindepend
fail
efficaci
freezedri
formul
furthermor
strain
genet
unstabl
revert
virul
anoth
typhi
strain
defect
gale
gene
well
defin
mutat
requir
extern
sourc
galactos
strain
extens
evalu
sever
field
trial
shown
excel
safeti
record
later
auxotroph
strain
unabl
synthesis
essenti
compound
like
aromat
amino
acid
develop
test
human
volunt
variabl
safeti
immunogen
result
attenu
live
vaccin
prevent
shigellosi
also
propos
genet
engin
select
mutant
shigella
tri
show
side
effect
clinic
trial
point
need
addit
attenu
without
hamper
immunogen
kotloff
et
al
attenu
guanin
auxotroph
shigella
flexneri
delet
two
gene
encod
enterotoxin
phase
trial
strain
inactiv
enterotoxin
gene
better
toler
still
immunogen
compar
guanin
auxotroph
strain
contain
activ
entoroxin
recombin
shigella
also
propos
vaccin
vehicl
pathogen
shigella
virul
plasmid
encod
protein
involv
thesecret
apparatu
protein
necessari
entri
process
human
cell
invas
capac
use
deliv
plasmid
dna
vaccin
mammalian
cell
deliv
plasmid
dna
encod
antigen
express
protein
synthesi
apparatu
infect
cell
diaminopimel
shigella
auxotroph
undergo
lysi
unless
diaminopimel
present
growth
media
human
cell
contain
low
amount
diaminopimel
upon
entri
shigella
mutant
lyse
make
deliveri
vaccin
compon
effect
attenu
bacteria
also
test
vaccin
vehicl
variou
protein
plasmid
dna
tabl
conclus
mimicri
natur
infect
make
attenu
bacteria
effect
abil
deliv
vaccin
compon
differ
origin
like
eg
hiv
piec
parasit
dna
gamet
specif
antigen
make
attenu
bacteria
versatil
vaccinolog
tool
howev
spite
effort
construct
attenu
pathogen
use
bacteri
vaccin
vehicl
none
reach
market
yet
potenti
use
lactic
acid
bacteria
lab
deliveri
vaccin
compon
less
exploit
attenu
pathogen
due
safe
statu
avail
genet
tool
recombin
gene
express
lab
attract
use
vaccin
vehicl
furthermor
nonpathogen
statu
circumv
need
construct
attenu
mutant
howev
lab
noninvas
vaccin
deliveri
antigen
present
cell
may
less
effect
invas
bacteria
still
antigen
specif
immun
respons
obtain
sever
lab
tabl
geoffroy
et
al
use
green
fluoresc
protein
visual
phagocytosi
lactobacillu
plantarum
macrophag
vitro
mice
macrophag
act
antigen
present
cell
explain
possibl
way
least
elicit
classii
mhc
receptor
present
antigen
even
though
transit
time
lactococcu
lacti
intestin
less
h
mice
potent
immun
respons
obtain
sever
antigen
includ
tetanu
toxin
fragment
c
ttfc
surprisingli
similar
respons
induc
use
dead
aliv
lactococcu
suggest
situ
antigen
synthesi
essenti
slightli
better
result
studi
obtain
l
plantarum
also
similar
respons
induc
live
uvlight
inactiv
cell
prospect
use
live
lab
vaccin
carrier
review
frequent
use
model
antigen
ttfc
good
result
obtain
intranas
oral
mice
model
use
strain
l
plantarum
l
lacti
grangett
et
al
test
cytoplasm
express
ttfc
antigen
l
plantarum
l
lacti
show
protect
effect
oral
mous
model
shaw
et
al
test
cytoplasm
surfac
associ
express
ttfc
antigen
found
cytoplasm
express
superior
surfac
expos
ttfc
l
lacti
contrast
et
al
test
human
papillomaviru
type
antigen
sort
differ
cellular
compart
found
cell
wallanchor
antigen
induc
potent
immun
respons
differ
outcom
experi
may
explain
differ
stabil
surfac
expos
ttfc
antigen
intracellular
express
labil
antigen
protect
proteolyt
degrad
environment
stress
encount
mucos
surfac
genet
modif
lab
cell
wall
render
strain
permeabl
increas
vivo
releas
cytoplasm
ttfc
antigen
test
grangett
et
al
administ
oral
alanin
racemas
mutant
immunogen
wild
type
counterpart
one
explan
could
oral
immun
depend
suffici
larg
dose
antigen
use
live
lab
carrier
dna
vaccin
option
noninvas
therefor
ineffici
deliv
plasmid
dna
cytoplasma
antigen
present
cell
recent
et
al
develop
l
lacti
express
cell
wallanchor
internalin
listeria
monocytogen
l
lacti
inla
strain
shown
enter
eukaryot
cell
vitro
also
vivo
use
oral
guinea
pig
model
determin
tropism
recombin
invas
strain
critchleythorn
el
al
use
perfus
bath
murin
ileal
tissu
test
invas
e
coli
vaccin
candid
although
chang
tropism
bacteri
carrier
open
target
deliveri
introduc
new
safeti
issu
address
persist
distribut
studi
bacteri
strain
vaccin
activ
vaccin
use
recombin
l
johnsonii
treat
allergi
suggest
ige
epitop
fuse
proteinas
prtb
cell
wallanchor
subcutan
intranas
immun
mice
induc
system
igg
respons
human
ige
allergyinduc
ige
may
clear
igg
antibodi
induc
recombin
l
johnsonii
howev
remain
proven
antibodi
protect
human
patient
conclus
lab
success
use
activ
vaccin
anim
like
rodent
tabl
whether
lab
effect
mucos
vaccin
human
answer
clinic
trial
furthermor
dose
recombin
lab
need
elicit
immun
respons
anim
high
unknown
necessari
dose
use
human
feasibl
cost
effect
protect
preform
antibodi
antibodi
fragment
call
passiv
vaccin
pioneer
experi
base
inject
antisera
produc
immun
anim
like
hors
sheep
combat
exampl
rattlesnak
venom
recent
passiv
immun
deliv
use
lactobacilli
secret
singlechain
antibodi
rat
cari
model
colonis
mouth
l
zeae
express
singlechain
antibodi
fragment
recogn
adhes
molecul
streptococcu
mutan
decreas
number
mutan
reduc
develop
cari
recombin
streptococcu
gordonii
display
microbiocid
singlechain
antibodi
use
treat
vagin
candidiasi
rat
model
although
passiv
immun
limit
temporari
natur
result
suggest
lab
elegantli
use
deliveri
neutralis
antibodi
mucos
site
normal
vaccin
infecti
diseas
induct
toler
infecti
agent
consid
side
effect
side
effect
prone
happen
vaccin
earli
life
howev
induct
toler
posit
clinic
implic
purpos
treat
allergi
mous
model
use
recombin
l
plantarum
express
hous
dust
mite
allergen
der
fusion
protein
cytoplasm
inhibit
hous
dust
mitespecif
tcell
respons
studi
mice
sensit
immun
hous
dust
mite
peptid
given
either
l
plantarum
express
der
l
plantarum
without
der
strain
inhibit
product
cell
decreas
product
seen
l
plantarum
express
der
peptid
antigen
indic
lactobacilli
strain
express
der
suppress
cytokin
milieu
promot
allerg
respons
anoth
exampl
strain
specif
effect
lab
induct
mainten
oral
toler
shown
use
gnotobiot
mice
studi
l
paracasei
ncc
effect
induc
maintain
oral
toler
gnotobiot
mice
l
johnsonii
ncc
allergen
also
coadminist
instead
recombin
express
lab
mucos
coapplic
l
plantarum
l
lacti
togeth
birch
pollen
allergen
bet
shift
immun
respons
toward
antiallerg
respons
sensit
unsensit
anim
recombin
strain
express
immun
polar
cytokin
like
also
develop
vivo
effect
mice
pig
observ
knowledg
mechan
behind
skew
immun
respons
howev
need
select
proper
strain
anti
allerg
immun
polar
furthermor
immun
regulatori
effect
one
strain
lab
may
differ
allerg
nonallerg
individu
regul
allerg
person
immun
stimul
effect
normal
person
observ
use
strain
lab
among
lab
effect
immun
system
strain
depend
induct
cytokin
differ
lab
strain
induc
distinct
mucos
cytokin
profil
balbc
mice
point
import
use
one
strain
immun
induct
anoth
induct
toler
partial
regul
immun
system
author
also
indic
growth
phase
depend
differ
oral
administ
lab
strain
antibodi
ratio
mice
complic
process
choos
proper
strain
specif
modul
immun
respons
ad
complex
observ
human
studi
shown
nonspecif
immun
modul
given
strain
l
rhamnosu
gg
atcc
differ
healthi
allerg
subject
healthi
person
strain
immun
stimulatori
wherea
allerg
person
downregul
inflammatori
respons
interact
differ
lab
strain
also
interfer
vitro
product
cytokin
dendrit
cell
shown
anoth
studi
two
differ
lactobacilli
similar
probiot
properti
vitro
shown
elicit
diverg
pattern
colonis
immun
respons
germfre
mice
evid
immun
modul
effect
seen
either
l
lacti
l
plantarum
use
mous
model
birch
pollen
allergi
combin
birch
pollen
allergen
bet
strain
skew
immun
respons
sensitis
mice
indic
ratio
immun
polar
effect
lab
also
observ
human
clinic
trial
show
strain
depend
immun
modul
two
differ
lab
strain
administ
togeth
oral
typhi
vaccin
thirti
healthi
volunt
randomis
three
group
receiv
l
rhamnosu
gg
l
lacti
placebo
day
day
vaccin
given
oral
analysi
show
higher
number
specif
igasecret
cell
group
receiv
l
rhamnosu
gg
higher
receptor
express
neutrophil
group
receiv
l
lacti
partial
regul
immun
system
also
observ
atop
children
receiv
l
rhamnosu
gg
daili
day
enhanc
product
sera
well
mitogeninduc
peripher
blood
mononuclear
cell
conclud
immun
polar
toward
either
respons
obtain
use
differ
lab
intrins
immun
modulatori
capac
lab
must
evalu
select
fit
purpos
vaccin
sever
safeti
concern
bacteri
vaccin
strain
rais
tabl
use
pathogen
bacteria
vaccin
purpos
pathogen
must
weaken
via
attenu
attenu
usual
involv
delet
essenti
virul
factor
mutat
gene
encod
metabol
enzym
whose
function
essenti
surviv
outsid
laboratori
inactiv
metabol
gene
advantag
bacteria
still
express
virul
determin
import
elicit
protect
immun
respons
appropri
stabl
auxotroph
strain
usual
abl
replic
human
bodi
safe
use
even
immun
compromis
individu
defin
delet
least
two
metabol
essenti
gene
usual
use
decreas
probabl
revers
virul
reduc
risk
spread
foreign
genet
materi
environ
antigen
encod
gene
cassett
insert
chromosom
replac
metabol
essenti
gene
bacterium
acquir
delet
gene
automat
loos
antigenencod
cassett
use
antibiot
resist
gene
marker
gene
vaccin
encourag
gene
transfer
end
human
thu
hamper
use
therapeut
antibiot
differ
altern
antibiot
resist
marker
gene
publish
use
soon
possibl
development
process
vaccin
anoth
concern
use
live
bacteri
vaccin
onset
autoimmun
respons
like
arthriti
especi
patient
tissu
type
howev
risk
certainli
lower
natur
infect
occurr
side
effect
best
follow
post
launch
monitor
must
alway
evalu
health
risk
associ
diseas
theoret
side
effect
vaccin
possibl
induct
autoimmun
reaction
howev
recommend
avoid
vaccin
peopl
ongo
autoimmun
diseas
like
rheumatoid
arthriti
system
lupu
erythematosu
vaccin
otherwis
motiv
contrast
immunecompromis
host
difficulti
handl
replic
live
attenu
vaccin
therefor
vaccin
vaccin
howev
new
way
attenu
bacteria
like
combin
auxotrophi
delet
virul
gene
may
open
use
live
vaccin
immunecompromis
host
addit
immunecompromis
peopl
close
host
vaccin
live
attenu
vaccin
awar
risk
cross
contamin
vaccin
strain
advers
exampl
human
live
vaccin
strain
caus
death
ill
among
domest
anim
rare
exist
mongolia
autumn
influenza
vaccin
viru
may
caus
sever
influenza
epizoot
among
camel
exampl
human
bacteri
vaccin
caus
problem
among
anim
found
literatur
possibl
exist
test
evalu
releas
live
bacteri
vaccin
gener
spread
live
bacteri
vaccin
environ
concern
howev
attenu
human
pathogen
usual
adapt
live
outsid
host
therefor
surviv
environ
usual
short
vaccin
base
recombinantlab
may
result
releas
bacteria
natur
lab
suit
surviv
natur
also
use
auxotroph
mutant
unabl
replic
environ
may
answer
releas
genemodifi
organ
environ
caus
debat
precaut
elimin
spread
essenti
avoid
escap
environ
genet
modifi
organ
steidler
et
al
replac
thya
gene
expressioncassett
human
consequ
l
lacti
mutant
depend
thymidin
thymin
growth
present
low
amount
natur
human
bodi
furthermor
acquir
intact
thya
gene
would
recombin
transgen
genom
result
revers
wild
type
state
live
bacteri
vaccin
antigenencod
gene
either
plasmid
locat
integr
chromosom
case
sever
safeti
concern
rais
tabl
plasmidencod
antigen
fate
plasmid
vaccine
must
evalu
use
prokaryot
plasmid
replic
unit
narrow
host
rang
limit
horizont
plasmid
transfer
bacteria
present
vaccin
individu
prevent
undesir
persist
plasmid
particular
plasmid
dna
vaccin
studi
identifi
cell
take
andor
express
dna
fate
dna
within
cell
well
long
dna
persist
cell
nasal
administr
nake
dnavaccin
mice
led
accumul
plasmid
dna
brain
illustr
diffus
plasmid
immun
amount
accumul
plasmid
accept
outsid
target
cell
need
clarifi
recombin
plasmid
harbour
bacteri
vaccin
vehicl
may
integr
genom
recipi
potenti
caus
oncogenesesi
concern
potenti
oncogen
biolog
product
like
continu
cell
line
product
ccl
dna
vaccin
gene
therapi
product
rais
ccl
foreign
dna
avoid
final
product
limit
defin
maxim
residu
amount
per
human
dose
dna
vaccin
dna
obviou
present
insert
dna
avoid
final
gene
therapi
product
dna
present
insert
insert
oncogenesi
avoid
integr
foreign
dna
host
genom
definit
insert
mutagenesi
induc
oncogenesi
three
way
extran
dna
lead
transform
insert
activ
oncogen
insert
activ
host
protooncogen
insert
deactiv
host
suppressor
gene
mechan
behind
dna
integr
chromosom
either
random
integr
homolog
recombin
retrovir
insert
probabl
caus
unwant
integr
random
integr
occur
frequenc
approxim
unwant
integr
homolog
recombin
retrovir
insert
avoid
omiss
sequenc
necessari
insert
analys
antigen
encod
unit
carri
bacteria
human
homolog
sequenc
elimin
limit
integr
possibl
although
similar
vaccin
bacteria
clinic
trial
use
retrovir
therapi
give
indic
hazard
dna
integr
inde
activ
oncogen
risk
associ
retrovir
vaccin
report
advers
effect
french
gene
therapi
studi
patient
develop
leukaemia
within
year
illustr
occurr
transform
event
activ
protooncogen
calcul
probabl
harm
effect
due
integr
foreign
dna
host
genom
perform
found
less
per
dna
molecul
frequenc
must
put
relat
spontan
mutat
frequenc
estim
human
occur
rate
everi
million
nucleotid
incorpor
dna
replic
mean
human
cell
base
pair
contain
new
mutat
possibl
insert
chromosom
test
pcr
techniqu
howev
insert
due
random
integr
difficult
detect
way
furthermor
insert
foreign
dna
effect
gene
activ
site
remot
insert
differ
anim
trial
foreseen
possibl
advers
effect
like
follow
two
exampl
foreign
dna
ingest
mice
shown
coval
link
mous
dna
foreign
dna
also
shown
associ
chromosom
fetus
born
mice
fed
oral
bacteriophag
dna
howev
evid
germ
line
transmiss
ingest
foreign
dna
de
novo
methyl
frequent
occur
integr
foreign
dna
suggest
natur
defenc
mechan
conclus
integr
plasmid
harbour
bacteri
vaccin
vehicl
potenti
hazard
integr
gene
therapi
vector
observ
omit
sequenc
drive
insert
may
limit
possibl
integr
plasmid
carri
bacterium
plasmid
heterolog
gene
express
usual
prefer
due
multi
copi
natur
higher
gene
dosag
howev
place
antigen
encod
gene
bacteri
chromosom
may
limit
spread
gene
rout
administr
vaccin
may
also
import
evalu
hazard
live
bacteri
vaccin
fit
mucos
administr
one
must
rememb
ingest
foreign
dna
occur
everi
day
food
new
peptid
absorb
mucosa
may
induc
allerg
reaction
exist
gene
bacteri
vaccin
code
potenti
allergen
injuri
peptid
check
beforehand
search
homolog
known
allergen
full
sequenc
bacteria
plasmid
known
vaccin
use
live
bacteri
vaccin
exposur
natur
infect
lead
format
auto
reactiv
antibodi
especi
peopl
prone
autoimmun
diseas
howev
half
life
induc
auto
antibodi
usual
short
specif
usual
polyclon
sever
author
tri
elucid
possibl
link
autoimmun
vaccin
much
controversi
matter
still
exist
howev
convinc
data
establish
link
vaccin
autoimmun
man
still
present
mous
model
differ
clinic
outcom
observ
two
differ
mous
strain
relat
autoantibodi
induc
vaccin
dendrit
cell
load
apoptot
thymocyt
normal
balbc
mice
presenc
post
vaccin
autoantibodi
associ
clinic
histolog
sign
autoimmun
howev
mice
prone
autoimmun
nzbxnzw
sever
patholog
attribut
autoimmun
observ
differ
outcom
attribut
differ
genotyp
also
observ
human
conclud
suscept
autoimmun
determin
genet
factor
vaccin
challeng
despit
format
post
vaccin
autoantibodi
vaccin
treatment
adjuv
also
activ
regulatori
cell
thu
use
method
prevent
autoimmun
diseas
appli
right
time
futur
tailormad
vaccin
might
solut
individu
genet
profil
prone
autoimmun
attenu
bacteria
like
salmonella
food
relat
lactic
acid
bacteria
develop
live
vaccin
suitabl
oral
administr
today
live
vaccin
base
attenu
typhi
v
cholera
avail
develop
bacteri
vaccin
vehicl
carri
heterolog
gene
dna
vaccin
problemat
none
yet
reach
market
sever
bacteria
suggest
vaccin
vehicl
especi
lactic
acid
bacteria
promis
safe
statu
immun
modul
capac
test
use
divers
vaccin
compon
like
antigen
infecti
diseas
allergi
promot
protein
therapeut
antibodi
howev
consider
safeti
issu
live
vaccin
vehicl
rais
recombin
natur
call
bio
contain
strategi
auxotroph
mutant
may
answer
bacteri
host
must
fulli
sequenc
evalu
use
bioinformat
tool
product
allergi
induc
peptid
antigen
encod
gene
cassett
must
sequenc
homolog
self
protein
allergi
induc
protein
address
especi
bacteria
carri
recombin
plasmid
probabl
horizont
gene
transfer
bacteria
present
avoid
use
host
restrict
replic
unit
furthermor
plasmid
evalu
sequenc
facilit
integr
human
genom
author
contribut
equal
work
